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Introduction
The optimal treatment of recurrent, platinum-sensitive
epithelial ovarian cancer (EOC) is still controversial [1]. In
fact, after a standard treatment at the time of diagnosis, con-
sisting in optimal cytoreduction followed by adjuvant plat-
inum-based chemotherapy, more than half of the patients
will recur [2] and eventually die [3]. Although many of
these relapses are platinum-sensitive, the best way to pro-
long the time to secondary progression and possibly to ex-
tend overall survival (OS) must still be defined.
Standard treatment of platinum-sensitive relapsed EOC is
considered platinum-based chemotherapy [4]. However, start-
ing from the front-line experience, which consolidates resid-
ual disease at the end of primary surgery as the principal
prognostic factor in the treatment of ovarian cancer, during
the last ten years secondary cytoreductive surgery [5] associ-
ated with perioperative intravenous chemotherapy obtained
encouraging results with five-years OS from 37 to 66 months
[6-10]. SCR associated with intraoperative administration of
hyperthermic intraperitoneal intraoperative chemotherapy
(HIPEC) has also been employed in EOC [11, 12], as well as
in several other malignancies like pseudomyxoma peritonei,
appendiceal, and colorectal cancer [13-17] with interesting
results. Since the clinical evidence supporting SCR ± HIPEC
in the setting of relapsed EOC is limited, these alternative
therapeutic approaches have not still received worldwide con-
sensus. 
In this context, the authors conducted a retrospective
analysis comparing progression-free survival (PFS) and OS
in women with platinum-sensitive (progression-free inter-
val or PFI > six months) EOC treated with either intra-
venous chemotherapy alone, SCR + intravenous
chemotherapy or SCR + HIPEC and intravenous
chemotherapy.
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Summary
Introduction: The best treatment for relapsed platinum sensitive epithelial ovarian cancer (EOC) is controversial. The aim of the
study was to compare progression-free survival (PFS) and overall survival (OS) in platinum-sensitive EOC patients treated with
chemotherapy alone (CTA), secondary cytoreductive surgery (SCR) or SCR plus hyperthermic intraperitoneal intraoperative chemother-
apy (HIPEC). Materials and Methods: Retrospective analysis of the clinical outcome of 46 EOC patients with at least 30 months of fol-
low-up. Results: Median follow-up time was 32 months for the CTA group, 30 months for the SCR group, and 45 months for the SCR
+ HIPEC group. Fifteen recurrences were observed in the CTA group, seven in the SCR group, and 16 in the SCR + HIPEC group. The
median time elapsed between first and second recurrence (PFI-2) was significantly higher among patients treated with SCR + HIPEC,
in comparison with patients treated with CTA (p = 0.012 and p = 0.017, respectively). On the contrary, PFI-2 did not significantly dif-
fer between the SCR and SCR + HIPEC groups (p = 0.877). A statistically significant difference in OS favouring SCR + HIPEC in com-
parison with CTA (p = 0.04) was observed. Conclusions: SCR ± HIPEC compared with CTA improves PFI-2 in patients with
platinum-sensitive EOC recurrence. SCR + HIPEC might also improve OS in comparison with CTA. No improvement in favor of SCR
+ HIPEC vs SCR was observed,. These results further support the need of a randomized trial comparing chemotherapy with SCR ±
HIPEC in this setting.
Key words: Secondary cytoreduction; HIPEC; Platinum sensitive relapse; Ovarian cancer; Platinum based chemotherapy; Cytoreduc-
tive surgery.
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Materials and Methods
Patients
The authors conducted a retrospective analysis of 46 patients with
first recurrence of platinum-sensitive EOC treated in two Italian In-
stitutions (Institute of Candiolo, IRCCS and Ospedale S. Giuseppe
Empoli) between 1995 and 2012 with one of the following treat-
ments: 1) intravenous platinum-based chemotherapy alone, 2) in-
travenous platinum-based chemotherapy associated with SCR or 3)
intravenous platinum-based chemotherapy associated with SCR and
HIPEC (SCR + HIPEC) 
The main inclusion criteria were: age ≥ 18 years, performance sta-
tus ECOG ≤ 1, patients with histologically documented first plat-
inum-sensitive recurrence of EOC (low grade and borderline
tumours were excluded), recurrence occurred at least six months
after completion of first-line treatment (PFI ≥ six months), and le-
sions confined to the abdominal cavity. All included patients had
normal cardiac, hepatic, respiratory, and bone marrow functions (e.g.
absolute neutrophils count > 1,500/µL, haemoglobin > 9 mg/dL,
platelets count > 150,000/µL, total bilirubin, and creatinine levels <
1.5 times the upper range). Patients affected by non-epithelial tu-
mors, low grade and borderline tumours, EOC relapses with extra-
abdominal, and/or intra parenchymal spread and those not submitted
to frontline optimal cytoreduction were excluded from the study
population.
Personal history, age, and ECOG performance status of the pa-
tients, as well as relevant data on diagnosis, treatment, and follow
were prospectively collected in an electronic database. Recurrence
diagnosis was determined by Ca125 serum level exponential rise
(increase to twice the upper limit of normal concentration) associated
with PET-TC and/or total body TC-scan evidence of neoplasia: re-
lapse extension and localization data were also collected. 
SCR treatment
Gynecologists and general surgeons constituted the medical team.
All patients underwent surgical laparotomic exploration with sub-
sequent maximum attempt to completely remove all sites of disease.
SCR, as well as primary cytoreductive surgery, demands a xifo-pubic
laparotomic access to the abdominal cavity: in order to achieve com-
plete cytoreduction, several procedures may be required, such as
hysterectomy and or bilateral salpingo-oophorectomy, if not previ-
ously performed, removal of bulky lymphadenopathy or radicaliza-
tion of previous lymphadenectomy, radicalization of omentectomy,
parietal and diaphragmatic peritoneal removal, splenectomy, single
or multiple ileal, colic or rectal resections, and subsequent anasto-
mosis or cutaneous stoma, and partial or complete cystectomy. At the
end of surgery, the completeness of cytoreduction was evaluated by
the following “Cytoreduction Completeness” (CC) score [18]: CC 0:
no residual tumor; CC 1: lesions < 0.25 cm; CC-2: lesions between
0.25 and 2.5 cm; CC-3: lesions > 2.5 c. “Optimal” SCR was intended
as CC0.
SCR plus HIPEC treatment
General surgeons and gynaecologic oncologists constituted the
medical team. Cytoreductive surgery attempted to remove all macro-
scopic disease by visceral resections and peritonectomy procedures
as described by Sugarbaker [19]. Peritonectomy extension was
recorded as the sum of peritonectomy sites, classified in five areas.
As for SCR alone, the completeness of cytoreduction was classified
according to the CC score [18].All HIPEC procedures were carried
out intraoperatively following cytoreductive surgery, with an origi-
nal semi-closed technique [20). HIPEC was performed for 60 min-
utes at a temperature of 41.5°C. The drugs used were cisplatin
(CDDP) 100 mg/m2 plus doxorubicin 15.2 mg/l. Patients were
treated postoperatively in the intensive care unit for at least 24 hours
(range 24–96 hours). 
Intravenous chemotherapy treatment
All patients were treated with platinum-based chemotherapy. The
most common doublet used was carboplatin AUC 6 and paclitaxel
175 mg/m2 for six cycles. One patient was treated with carboplatin
AUC 5 and pegylated liposomal doxorubicin (Caelyx) and other two
patients received the doublet carboplatin and cyclophosphamide or
gemcitabine. Three patients received carboplatin or cisplatin as sin-
gle agents. At the end of secondary treatment all groups were sub-
mitted to an identical follow up regimen: periodical visits occurred
every three months during the first year and every six months in the
following years, and included physical and gynaecological exami-
nations, pelvic ultrasound examination, quality of life assessment,
and a CA125 essay. PET-TC and/or total body TC-scan were just
performed at Ca125 exponential rise, on clinical indication or in
symptomatic disorders. At the end of secondary treatment, all groups
were submitted to an identical follow up regimen: periodical visits
occurred every three months during the first year and every six
months in the following years and included physical and gynaeco-
logical examinations, pelvic ultrasound examination, quality of life
assessment, and a CA125 essay. PET-TC and/or total body TC-scan
were just performed at Ca125 exponential rise, on clinical indica-
tion or in symptomatic disorders.
Statistical analysis
The authors named primary platinum-free interval (PFI-1) the
time elapsed between the end of primary treatment and the first re-
currence. The duration of second response or secondary platinum-
free interval (PFI-2) was defined as the time elapsed between the
first recurrence and the second recurrence or date of last follow-up.
They defined OS as the time elapsed from the second recurrence to
the date of death or the date of last follow-up. All patients reached
at least 24 months of follow-up. The response to treatments and pro-
gression was estimated according to the Gynecological Cancer In-
tergroup (GCIG) response criteria [21], using both serological and
radiological criteria. In brief, complete response (CR) consisted in
the disappearance of all known disease on CT scan and return of
serum CA-125 levels to normal values (35 IU/ml) for at least four
weeks. Partial response (PR) was considered to be a 30% decrease
in the sum of the longest diameter of target lesions (evaluated by CT
scan) in measurable disease or a 50% decrease in serum levels of
CA-125 (confirmed with repeat serum CA-125 level assessments in
no less than four weeks). Progressive disease (PD) was considered
to be appearance of new lesions or more than 30% increase in the
sum of the longest diameter of target lesions (evaluated by CT scan)
in measurable disease or increase in serum levels of CA-125 more
than two-fold the nadir value in non-measurable disease. At the end
of secondary treatment, all groups were submitted to an identical
follow up regimen: periodical visits occurred every three months
during the first two years and every six months during the following
years, and included physical and gynaecological examinations,
pelvic ultrasound examination and CA125 dosing. PET-TC and/or
total body TC-scan were just performed when CA 125 exponentially
increased, or at the onset of symptoms.
Comparisons between categorical variables were evaluated by the
Chi Square or the Fisher’s exact test. Survival curves were compared
by the log-rank test. Statistical significance was set at p < 0.05. All
the analyses were conducted with the SPSS 20.0 statistical package. 
Ethical approval statement
In Italy, the National Regulation established that retrospective stud-
ies require a notification to the local ethical committee with the tacit
consent formula. The authors therefore notified to the Candiolo Can-
cer Center ethical committee of the conduction of the study on Jan-
uary 17, 2015. All patients included in this retrospective study were
treated according to the ethical standards of the local committee on
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human experimentation and with the Helsinki Declaration.
Results
Patients’ characteristics
The authors included 46 patients: 16 patients were treated
with intravenous chemotherapy alone (CTA group), 11 pa-
tients were treated with secondary cytoreductive surgery and
perioperative intravenous platinum-based chemotherapy
(SCR group), and 19 patients with secondary cytoreductive
surgery in association with hyperthermic intraperitoneal
chemotherapy and perioperative intravenous platinum-
based chemotherapy (SCR + HIPEC group). Patients’ base-
line characteristics are summarized in Table 1. Baseline
characteristics were similar for all variables considered. The
median age at diagnosis was 57.7, 56.3, and 51.3 years for
the CTA, SCR, and SCR + HIPEC groups, respectively.
Most patients had high-grade (G3), Stage III, serous ep-
ithelial carcinoma at diagnosis. CA 125 levels at diagnosis
were similar in all groups. At relapse, most patients had el-
evated CA 125, with no differences of the means among
groups. The median PFI-1 was similar for all groups (18.1,
25.9 and 22.0 months for CTA, SCR, and SCR + HIPEC
groups, respectively). Surgical details, including cytoreduc-
tive procedures and mean hospital stay are shown in Table
2.
Outcome of second-line treatment
Complete cytoreduction, defined as the absence of
macroscopic disease, was obtained in all patients who un-
derwent surgery (SCR and SCR + HIPEC groups). No pa-
tients submitted to CTA, had a complete remission defined
as absence of detectable disease at computed tomography
(CT scan) and Ca 125 levels < 35 ml/UI. 
Survival analysis
Survival data following second line treatment are shown
in Figures 1A and 1B. The median follow-up time was 32.9
months for the CTA group, 30.4 months for the SCR group,
and 45.4 months for SCR + HIPEC group. During this pe-
riod, 15, 7, and 16 recurrences were observed in the CTA,
Table 1. — Patient characteristics.
SCR SCR +HIPEC CTA p value
N= 11 (%) N= 19 (%) N= 16 (%)
Age, years (mean) 56.27 51.26 57.69 0.139
Histology 0.843
Serous 7 (63.6) 11 (57.9) 9 (56.3)
Endometrioid 1 (9.1) 3 (15.8) 1 (6.3)
Clear cell 0 (0) 0 (0) 1 (6.3)
Mucinous 0 (0) 1 (5.3) 0 (0)
Undifferentiated 2 (18.2) 3 (15.8) 3 (18.8)
Unknown 1 1 (5.3) 2 (12.5)
Grade 0.074
2 3 (27.2) 0 (0) 1 (6.2)
3 6 (54.5) 12 (63.1) 9 (56.2)
Unknown 2 (18.1) 7 (36.8) 6 (37.5)
Stage 0.121
1 2 (18.1) 1 (5.3) 0 (0)
2 2 (18.1) 1 (5.3) 2 (12.5)
3 6 (54.5) 11 (57.9) 11 (68.7)
4 0 (0) 2 (10.5) 0 (0)
Unknown 2 (18.1) 3 (15.7) 0 (0)
Ca125 at
diagnosis (mean) 1204 529 1101 0.699
Ca125 
at relapse (mean) 82 59 201 0.331
Ascites (ml) 0.522
< 500 10 (91) 3 (15.7) 12 (75)
> 500 1 (9) 1 (5.3) 2 (12.5)
Unknown 0 (0) 15 (79) 2 (12.5)
Residual tumor after first surgery 0.309
R0 9 (82) 14 (74) 7 (44)
R1 0 (0) 3 (16) 3 (19)
R2 0 (0) 2 (10) 2 (12.5)
Unknown 2 (18) 0 (0) 4 (25)
ECOG at relapse 0.04
0 8 (73) 11 (58) 12 (75)
1 1 (9) 0 (0) 4 (25)
Unknown 2 (18) 8 (42) 0
Tumor locations
Pelvis 2 (18.2) 4 (23.5) 1 (6.7) –
Retroperitoneal 4 (36.4) 0 (0) 2 (13.3) –
Peritoneum 5 (45.5) 13 (76.5) 11 (73.3) –
Liver 0 (0) 0 (0) 1 (6.7) –
Legend: SCR: secondary cytoreductive surgery; CTA: chemotherapy alone;
HIPEC: hyperthermic intraperitoneal chemotherapy;
PFI-1 primary progression-free interval.
Table 2. — Characteristics of surgery.
SCR SCR+HIPEC
(N 11) (N19)
SURGICAL DETAILS, mean (range)
Duration of surgery, minutes 233 (90-460) 461 (48-720)
Blood loss, ml 362 (100-1200) NA
Mean hospital stay, days 8.4 (3-25) .25 (16-36)
SURGICAL PROCEDURES
Hysterectomy (%) 0 (0) 1 (5.3)
Ovariectomy 0 (0) 1 (5.3)
Omentectomy 3(27.3) 18 (94.7)
Pelvic lymphadenectomy 4 (36) 8 (42)
Para-aortic lymphadenectomy 6 (54) 7 (36.8)
Other lymphadenectomy 3 (27) 0 (0)
Pelvic peritonectomy 6 (54) 12 (63)
Paracolic peritonectomiy 3 (27.3) 9 (47.4)
Diaphragmatic peritonectomy 2 (18.2) 8 (42)
Colon resection 4 (36) 7 (36.8)
Intestinal resection 0 (0) 3 (15.8)
Splenectomy 0 (0) 5 (26.3)
Liver resection 1 (9.1) 3 (15.8)
Legend: SCR: secondary cytoreductive surgery;
HIPEC: hyperthermic intraperitoneal chemotherapy;
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SCR and SCR + HIPEC groups, respectively.
The median PFI-2 was significantly different in the CTA,
SCR, and SCR + HIPEC groups (13.2 months, 23.0 and
19.9 months, respectively; p= 0.009). PFI-2 was signifi-
cantly higher among patients treated with SCR and SCR +
HIPEC as compared to patients treated with CTA (p = 0.012
and p = 0.017, respectively). On the contrary, PFI-2 did not
significantly differ between the SCR and SCR + HIPEC
groups (p = 0.877) (Table 3).
During the follow-up period, a total of 27 deaths were
observed: 13 belonged to the CTA group, three to the SCR
group, and 11 to the SCR + HIPEC group. The median sur-
vival has not yet been reached in the SCR group. Patients
in the SCR + HIPEC group survived significantly longer
than patients in the CTA group, with a median OS of 51.5
versus 35.6 months, respectively (p = 0.040) (Figure 1B). 
Interestingly, when the authors compared PFI-2 with PFI-
1 for each treatment group, they observed a statistically sig-
nificant reduction of PFI-2 vs PFI-1 only in the CTA group
(p = 0.012) (Table 4).
Toxicities
As expected, chemotherapy alone was the less toxic treat-
ment with only few cases of febrile neutropenia and no se-
rious adverse effects (Table 5); interestingly, however, no
treatment related deaths were observed in the SCR and SCS
+ HIPEC groups [22]. 





tion of patients alive
following second-line
treatment.
Table 3. — Comparison of secondary progression-free in-
terval (PFI-2) among groups
Variable SSCR SCR + HIPEC CTA p value
(months) (months) (months)
PFI-2 23,031 19,877 13,207 0.009
23,031 . 13,207 0.012
23,031 19,877 . 0.877
. 19,877 13,207 0.017
OS . 51,483 35,647
. . 35,647
. 51,483 .
. 51,483 35,647 0.040
FU 30,423 45,357 32,868 0.044
Legend: SCR: secondary cytoreductive surgery; CTA: chemotherapy alone;
HIPEC: hyperthermic intraperitoneal chemotherapy;
PFI progression-free interval; OS: median overall survival,
not reached for SCR group FU: median follow up.
Table 4. — Comparison of duration of primary (PFI-1) and
secondary (PFI-2) disease-free interval among groups.
PFI-1 (months) PFI-2 (months) p value 
SCR 22.14 23.03 0.499
SCR + HIPEC 21.98 19.88 0.903
CTA 20.01 13.21 0.013
Legend: CTA: chemotherapy alone; SCR: secondary cytoreductive surgery;
HIPEC: hyperthermic intraperitoneal chemotherapy;
PFI: progression-free interval.
Table 5. — Treatment-related complications.
CTA SCR SCR + HIPEC
(N =16) (N = 11) (N=19)
Adverse events (%) Any Above Any Above Any Above
G3 G3 G G3 G G3
Re-laparotomy 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 1 (5)
Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 2 (11) 2 (11)
Bleeding 0 (0) 0 (0) 1 (9) 0 (0) 0 (0) 0 (0)
Pulmonary embolism 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0)
Infection 0 (0) 0 (0) 1 (9) 0 (0) 1 (5) 0 (0)
Leukopenia 0 (0) 0 (0) 1 (9) 0 (0) 1 (5) 0 (0)
Paralytic ileus 0 (0) 0 (0) 1 (9) 0 (0) 0 (0) 0 (0)
Surgical complications were scored following the Clavien-Dindo [28]
classification; medical complications were scored using the CTCAE v3 criteria.
CTA: chemotherapy alone; SCR: secondary cytoreductive surgery;
HIPEC: hyperthermic intraperitoneal chemotherapy.
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Discussion
At present, the optimal treatment of platinum-sensitive
recurrent EOC remains controversial. For patients who
experience platinum-sensitive relapse, platinum-based
chemotherapy has long been considered the standard
treatment. In these patients, the combination of platinum
with taxanes, gemcitabine, or pegylated liposomal dox-
orubicin is associated with a median survival of 29, 18,
and 31.5 months respectively [23, 24]. 
A large body of data from non-randomized studies has
accumulated over the years, suggesting that also SCR
may have a role and could significantly prolong survival
in selected patients with relapsed EOC. A recent meta-
analysis, conducted in forty cohorts of patients with re-
current ovarian cancer (2,019 patients) submitted to SCR,
demonstrated that the only clinical parameter signifi-
cantly associated with post-recurrence survival was the
achievement of complete cytoreduction (i.e. absence of
any macroscopic residual disease) [25]. Indeed, complete
SCR may be associated with prolonged survival, with
some studies reporting median survival times ranging be-
tween 45 and 61 months [26, 27]. However, in these pa-
tients for whom complete cytoreduction cannot be
achieved, surgery may have a potentially detrimental ef-
fect due to its associated morbidity and to the delay of
more effective approaches.
Over the least 20 years, cytoreductive surgery has been
also associated with HIPEC in the treatment of various
peritoneal malignant diseases with contradictory results
[12, 13, 20]. In a recent systematic review, it was reported
that HIPEC after cytoreductive surgery in EOC was as-
sociated with a median DFS ranging from 10 to 57
months and a median OS ranging from 22 to 64 months,
suggesting that it may be a feasible option for patients
with advanced or recurrent ovarian cancer [11]. In the
setting of recurrent EOC, three case-control studies have
been published comparing SCR plus chemotherapy ver-
sus the same treatment plus HIPEC and they all show sig-
nificantly higher five-year OS rates for SCR + HIPEC
(50-68%) as compared to SCR alone (17-42%) [12, 28,
29].
In the present study the authors attempted to add fur-
ther information on the subject by also including in the
analysis a group of patients with comparable baseline
characteristic who received platinum-based chemother-
apy without any surgery, in order to compare the three
currently available options in platinum sensitive recur-
rent ovarian cancer. 
Since the duration of response after first recurrence
becomes progressively shorter, the ability of a treatment
to pair the time of the primary response is a crucial test
for any experimental approach [12]. Harrison et al. in
their retrospective analysis of 35 patients with relapsed
EOC submitted to second-line platinum-based
chemotherapy found that the median duration of PFI-2
was shorter as compared to PFI-1 (10.8 vs 17.8 months,
respectively), with only three patients (9%) showing a
PFI-2 longer than PFI-1 [30]. Accordingly, in the present
series the authors observed a significant reduction in
PFI-2 vs PFI-1 in the CTA group. Conversely, the medi-
ans of PFI-2 and PFI-1 both in the SCR (25 months vs 23
months) and SCR plus HIPEC (21 months vs 19 months)
groups were comparable. Moreover, they observed a sig-
nificantly longer PFI-2 both for the SCR and the SCR +
HIPEC groups vs the CTA group. 
The present data are consistent with a possible inferi-
ority of the “chemo-alone” approach in platinum-sensi-
tive relapsed EOC in comparison with the “surgery +
chemo” approaches. On the contrary, the present authors
were not able to demonstrate any significant difference
from the addition of HIPEC to SCR, perhaps due the lim-
ited number of patients compared. Therefore, both SCR
and SCR + HIPEC appear superior to CTA in terms of
PFS-2, at least in patients with good performance status
and without extra-abdominal diffusion of the disease.
Although a detailed treatment-related morbidity and
mortality analysis was out of the aim of this study, the
authors substantially confirmed that SCR and SCR plus
HIPEC are feasible procedures thanks to recent pro-
gresses in more accurate perioperative care, increased
surgical expertise, and safer administration of chemother-
apy with very low risk of severe morbidities
The strength of the present results is the homogeneity
of the analyzed groups, with no significant differences
between them in terms of PFI-1, histotype, grading, stage
at diagnosis, CA125 at diagnosis and at relapse, residual
disease after primary surgery, and amount of ascites at
relapse. The weakness of the study is, obviously, its ret-
rospective design and the small number of patients in
each group.
In conclusion, this retrospective study comparing the
effect of different treatments in platinum-sensitive re-
current ovarian cancer patients adds further evidence on
the role of SCR in relapsed platinum sensitive ovarian
cancer. On the contrary, the absence of a significantly sta-
tistically difference between SCR and SCR ± HIPEC in
terms of PF-2 and OS does not support the use of SCR +
HIPEC in this setting.
Results from phase-III studies comparing survival rates
in women submitted to SCR plus HIPEC vs SCR alone
(NCT01539785) and results of the DESKTOP III trial
(NCT01166737) comparing survival rates in women sub-
mitted to chemotherapy alone (control) or cytoreductive
surgery followed by chemotherapy are being awaited
with interest.
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